MTOR and neoplasm: Despite recent advances in targeted therapies, such as tyrosine kinase, mechanistic target of rapamycin (mTOR) inhibitors, and immune checkpoint inhibitors (ICIs), the development of drug resistance and tumor heterogenicity hamper these efforts, whereas metastatic disease poses a serious clinical problem 2.